Breast cancer survivors treated with taxanes, vascular endothelial growth factor (VEGF) inhibitor, and hormonal agents experience increased thrombotic events, severe hypertension, and heart failure [38,39]. This evidence concerns the gene VEGFA and breast carcinoma.